The decision made on Monday by Britain’s Medicines & Healthcare products Regulatory Agency (MHRA) was based on credible claims that CBD successfully treats serious diseases. While the DEA has been busy reclassifying cannabidiol (CBD) as a Schedule I drug—right up there with heroin—our friends across the pond are rightly classifying it as a medicine. In early December, researchers from the University of Alabama found that CBD oil reduces both the frequency and severity of seizures in children and adults with with severe, intractable epilepsy. In two-thirds of the 81 participants, the severity was reduced by at least 50 percent. In view of the fact that UK-based GW Pharmaceuticals has made huge strides recently with its CBD-based Epidiolex for rare, treatment-resistant epilepsy, the MHRA’s decision makes perfect sense.
While the DEA has been busy reclassifying cannabidiol (CBD) as a Schedule I drug—right up there with heroin—our friends across the pond are rightly classifying it as a medicine.
The decision made on Monday by Britain’s Medicines & Healthcare products Regulatory Agency (MHRA) was based on credible claims that CBD successfully treats serious diseases.
The new classification means products containing CBD can now be legally distributed across the United Kingdom.
“We have come to the opinion that products containing cannabidiol (CBD) used for medical purposes are a medicine,” said an MHRA spokesperson on the agency’s website....
Read the full article @ High Times